Health Care & Life Sciences » Biotechnology | Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Agios Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Health Care Fund
4,233,424
7.3%
-119,700
0.68%
06/30/2018
BB Biotech AG
2,535,253
4.37%
-214,745
4.93%
03/31/2018
Fidelity Growth Company Fund
2,255,462
3.89%
-12,238
0.38%
07/31/2018
American Funds New Perspective Fund
2,086,622
3.6%
0
0.21%
06/30/2018
Hartford Mid Cap Fund
1,532,864
2.64%
48,574
0.93%
07/31/2018
Fidelity Contrafund
1,425,333
2.46%
-6,628
0.09%
07/31/2018
Vanguard Small Cap Index Fund
1,231,761
2.12%
15,964
0.1%
07/31/2018
Vanguard Total Stock Market Index Fund
1,231,153
2.12%
8,852
0.01%
07/31/2018
ClearBridge Aggressive Growth Fund
1,057,216
1.82%
-4,840
0.69%
12/31/2017
Fidelity Advisor New Insights Fund
898,962
1.55%
0
0.25%
07/31/2018

About Agios Pharmaceuticals

View Profile
Address
88 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.agios.com
Updated 07/08/2019
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Its product candidates include IDHIFA, ivosidenib, AG-881, AG-348, and AG-270.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.